ORGO (Organogenesis Holdings) Total Liabilities : $112.6 Mil (As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Organogenesis Holdings Total Liabilities?

Organogenesis Holdings's Total Liabilities for the quarter that ended in Dec. 2024 was $112.6 Mil.

Organogenesis Holdings's quarterly Total Liabilities declined from Jun. 2024 ($179.66 Mil) to Sep. 2024 ($167.75 Mil) and declined from Sep. 2024 ($167.75 Mil) to Dec. 2024 ($112.57 Mil).

Organogenesis Holdings's annual Total Liabilities declined from Dec. 2022 ($183.69 Mil) to Dec. 2023 ($181.36 Mil) and declined from Dec. 2023 ($181.36 Mil) to Dec. 2024 ($112.57 Mil).

Organogenesis Holdings Total Liabilities Historical Data

The historical data trend for Organogenesis Holdings's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Organogenesis Holdings Total Liabilities Chart

Organogenesis Holdings Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

148.41

201.92

183.69

181.36

112.57

Organogenesis Holdings Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															181.36	180.45	179.66	167.75	112.57

Organogenesis Holdings Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Organogenesis Holdings's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	77.477	+	(34.199	+	0.89399999999999
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	112.6

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	497.886	-	385.316
	=	112.6

Organogenesis Holdings's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	77.477	+	(34.199	+	0.89399999999999
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	112.6

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	497.886	-	385.316
	=	112.6

Organogenesis Holdings Total Liabilities Related Terms

Thank you for viewing the detailed overview of Organogenesis Holdings's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Organogenesis Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Organogenesis Holdings Inc (NAS:ORGO) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

85 Dan Road, Canton, MA, USA, 02021

Website

https://www.organogenesis.com

Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.

Executives

Michael Joseph Driscoll	director	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Gary S. Gillheeney	director, officer: President and CEO	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Albert Erani	10 percent owner	150 DAN ROAD, 150 DAN ROAD, CANTON MA 01002
Michael W Katz	10 percent owner
Arthur S Leibowitz	director	139 SOUNDVIEW DRIVE, PORT WASHINGTON NY 11050
Gilberto Quintero	director	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Michele Ilene Korfin	director	17 STATE STREET, 7TH FLOOR, NEW YORK NY 10004
Antonio S. Montecalvo	officer: VP Health Policy & Contracting	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Jon L Giacomin	director	7000 CARDINAL PLACE, DUBLIN OH 43017
David Francisco	officer: Chief Financial Officer	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Red Holdings, Llc	10 percent owner	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Prathyusha Duraibabu	director	C/O SANGAMO THERAPEUTICS, INC., 501 CANAL BLVD., RICHMOND CA 94804
Glenn H Nussdorf	director, 10 percent owner
Alan A. Ades	director, 10 percent owner	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Gn 2016 Organo 10-year Grat U/a/d September 30, 2016	10 percent owner	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021